Acotec and Boston Scientific Sign Memorandum of Understanding

Acotec Scientific Holdings Limited (“Acotec”, stock code: 6669.HK) and Boston Scientific Corporation ("Boston Scientific", stock code: NYSE: BSX) today announced that the companies signed a memorandum of understanding (“MOU”) on June X, 2023, marking a new chapter in the commercial collaboration between the two parties.


Based on the MOU, Acotec and Boston Scientific will explore practical ways to leverage their respective industry experience, innovative technology, production capabilities and resources to promote collaboration in the areas of research and development, manufacturing and commercialization. First, the two parties will explore opportunities to strengthen research and development (R&D) capabilities in the field of cardiovascular disease while maintaining close cooperation in the development of products. Second, the two parties will explore the possibility of providing original equipment manufacturer (OEM) services to achieve the goal of optimizing cost-effectiveness for both companies. Third, Acotec and Boston Scientific will engage in cross-selling and co-branding activities for certain products across both companies’ portfolios and may also provide registration support for one another.


Regarding the signing of the MOU, Ms. Li Jing, CEO of Acotec, stated:


"Through this strategic collaboration, Acotec will gain an opportunity to enhance our own R&D and manufacturing capabilities while embracing the global market, and the benefits brought by diversified businesses will help Acotec thrive. Moving forward, Acotec will work together with Boston Scientific to develop and implement feasible plans, thereby fulfilling Acotec's initial goal of addressing unmet clinical needs and benefiting patients globally."